Pricing Log in Create free account
Saturday 17 October 2026 Export MDWD’s income statement to Excel — free account

MediWound Ltd.

MDWD Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.85 0.36 −2.95%
Market cap
$157.6M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.05
Beneish M
−3.69
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.14
Total sells 0.08
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 1 2 — — — —
Sell — — — — — — — — — 1 1 —
Insider Ownership 25.33%

Capital & Financial Ratios $m

Market Cap 157.63
Revenue 11.86
Net Income (20.18)
Free Cash Flow (28.53)
Net Debt (35.34)
Current Ratio 2.32 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.14) (negative: loss-making)
P/S ratio 12.87 (above 10: high)
P/B ratio 4.28
Past 5Y EPS Growth —
This Y EPS Growth (4.37%) (below 0%: weak)
Next Y EPS Growth (0.30%) (below 0%: weak)
Next Y revenue growth 39.57% (at or above 10%: strong)
Next 5Y EPS Growth 16.86% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 10.0×, against a ten-year median of 6.9×; over the ten years it ranged from 0.5× in 2020 to 216× in 2016.
P/S against its own 10 years 63.14%
10-year low 10-year high
P/B against its own 10 years 16.23%
10-year low 10-year high
EV/Sales against its own 10 years 62.92%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 42 43 53 35
Receivables 5 6 3 3
Inventory 3 3 4 4
Other — — — —
50 52 60 43
2023 2024 2025 Q'26
Payables 6 5 8 8
ST’ Debt — — — —
Other 9 18 14 6
18 27 26 19

Compound Annual Growth %

10y 5y 3y
Sales 39.65% (4.87%) (13.82%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 6.40% 43.10% 58.71%

Revenue $m

Mar Jun Sep Dec Year
’26 1 3 — — —
’25 4 6 5 2 17
’24 5 5 4 6 20
’23 4 5 5 5 19
’22 4 5 6 12 26
’21 6 6 6 5 24
’20 4 4 7 7 22
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) (9) — — —
’25 (4) (6) (3) (3) (16)
’24 (5) (4) (4) (2) (14)
’23 1 (5) (3) (3) (10)
’22 (4) (5) (5) 2 (12)
’21 (3) (1) (3) (2) (9)
’20 (2) (3) 1 (3) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (10) — — —
’25 (5) (7) (4) (5) (22)
’24 (6) (7) (5) (2) (20)
’23 (1) (6) (5) (5) (17)
’22 (4) (5) (5) 2 (12)
’21 (3) (1) (3) (2) (9)
’20 (2) (3) 1 (4) (8)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.23) (0.56) — — —
’25 (0.07) (1.23) (0.24) (0.56) (2.10)
’24 (1.05) (0.68) (0.98) (0.36) (3.03)
’23 (0.44) 0.10 (0.24) (0.19) (0.75)
’22 (0.84) (0.91) (0.91) (1.18) (3.93)
’21 (0.70) (0.84) (0.84) (1.05) (3.50)
’20 (0.63) (0.77) (0.49) (0.42) (2.38)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 29.75 29.05 24.90 17.84 10.10 15.40 8.05 7.10 10.20 14.14

Analyst estimates 2026–2028

Powerpack
High 65.03 57.75 51.45 42.63 31.08 43.54 23.66 14.58 24.00 22.51
People
People Employees 72 76 61 74 75 77 83 88 111 121
Revenue/emp, $m 0.02 0.03 0.06 0.43 0.29 0.31 0.32 0.21 0.18 0.14
Income, $m
Income, $m Revenue 2 2 3 32 22 24 26 19 20 17
Gross margin, % (38.51) 36.78 38.61 62.73 34.67 36.91 49.69 19.15 13.03 19.19
EBT (19) (15) (6) 2 (9) (14) (20) (7) (30) (24)
EBT margin, % (1,212.13) (582.25) (166.57) 6.50 (42.62) (56.91) (73.68) (34.95) (149.16) (139.81)
Net income (19) (22) (1) 5 (9) (14) (20) (7) (30) (24)
Depreciation 1 1 1 1 1 1 1 1 1 2
Per share, $
Per share, $ Revenue 0.50 0.75 0.88 8.18 5.60 6.11 5.31 2.07 2.03 1.49
Earnings (6.02) (6.65) (0.28) 1.26 (2.38) (3.50) (3.93) (0.75) (3.03) (2.10)
Cash flow (5.26) (4.93) (3.14) 2.13 (1.77) (2.29) (2.38) (1.16) (1.37) (1.42)
Capex (0.22) (0.32) (0.14) (0.20) (0.24) (0.13) (0.11) (0.72) (0.63) (0.48)
Free cash flow (5.49) (5.26) (3.27) 1.93 (2.01) (2.42) (2.49) (1.88) (2.00) (1.90)
Book value 2.49 2.88 2.32 3.91 1.87 (1.18) 2.19 3.51 3.13 3.84
Shares, m 3 3 4 4 4 4 5 9 10 11
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 17.23 0.00 0.00 0.00 0.00 0.00 0.00
P/S 73.69 42.56 32.38 2.65 4.63 2.71 2.50 5.43 8.77 12.38
P/B 14.78 11.04 12.27 5.56 13.85 0.00 6.07 3.21 5.69 4.81
EV/Sales 54.51 28.17 25.47 1.74 3.66 2.27 1.24 3.31 6.66 9.30
EV/FCF (4.91) (4.00) (6.81) 7.43 (10.14) (5.70) (2.64) (3.64) (6.76) (7.28)
Cash, $m
Cash, $m Operating cash flow (16) (16) (12) 8 (7) (9) (12) (10) (14) (16)
Capex (1) (1) (1) (1) (1) 0 (1) (6) (6) (6)
Free cash flow (17) (18) (13) 7 (8) (9) (12) (17) (20) (22)
Balance, $m
Balance, $m Working capital 28 36 28 25 18 4 34 32 26 34
Total debt — — — 3 2 2 1 — — —
Net debt (30) (36) (24) (29) (22) (11) (34) (42) (43) (53)
Shareholders’ equity 8 10 9 15 7 (5) 11 32 31 44
Returns, %
Returns, % ROA (42.78) (55.44) (2.66) 13.06 (25.67) (53.34) (56.19) (11.53) (43.19) (29.90)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (120.90) (254.73) (11.37) 41.05 (81.96) (1,007.51) (619.05) (31.60) (96.33) (63.86)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

MediWound Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CHRS Coherus Oncology, Inc. $165.3M — (loss-making) — (loss-making) +39.53% (above 0%: growing) n/m −33.15% (below 0%: shrinking) 70.35% (225.98%) Compare
IPHA Innate Pharma S.A. Sponsored ADR $165.3M — (loss-making) — +246.29% (above 0%: growing) +106.08% (above 0%: growing) −929.03% (below 0%: shrinking) 0.00% 0.00% Compare
VRXA Veraxa Biotech AG $162.5M — — — — — — — Compare
CMPX Compass Therapeutics, Inc. $161.5M — (loss-making) — (loss-making) — n/m −26.05% (below 0%: shrinking) 100.00% 0.00% Compare
ADAG Adagene Inc. Sponsored ADR $161.1M — (loss-making) — (loss-making) — — −11.08% (below 0%: shrinking) — — Compare
MDWD MediWound Ltd. $157.6M — (loss-making) — (loss-making) −45.83% (below 0%: shrinking) n/m −49.90% (below 0%: shrinking) 10.90% (305.89%)
NBP NovaBridge Biosciences $149.6M — (loss-making) — (loss-making) −88.54% (below 0%: shrinking) n/m +34.25% (above 0%: growing) 100.00% 0.00% Compare
CNTN Canton Strategic Holdings, Inc. $149.0M 9.0× — — n/m −600.39% (below 0%: shrinking) 100.00% (80.37%) Compare
CDXS Codexis, Inc. $148.9M — (loss-making) — (loss-making) −2.69% (below 0%: shrinking) n/m +48.60% (above 0%: growing) 76.45% (75.29%) Compare
Median of peers $161.3M — — +18.42% — −26.05% 88.23% (37.64%)

All 614 Biotechnology stocks →

MediWound Ltd. (MDWD) key facts

  • Concern: MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024.
  • MediWound Ltd. (MDWD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MDWD traded at $11.85, a market capitalization of $157.6 million.
  • Return on equity was −63.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −1.05 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

MediWound Ltd. (MDWD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MDWD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com